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ABSTRACT 34 
HLA-B*57:01 and HLA-B*57:03, the most prevalent HLA-B*57 subtypes in Caucasian and 35 
African populations, respectively, are the HLA alleles most protective against HIV disease 36 
progression. Understanding the mechanisms underlying this immune control is of critical 37 
importance and yet remains unclear. Unexplained differences are observed in the impact of the 38 
dominant CTL response restricted by HLA-B*57:01 and HLA-B*57:03 in chronic infection 39 
towards the Gag epitope KAFSPEVIPMF (‘KF11’,Gag162-172). We previously showed that the 40 
HLA-B*57:03-KF11 response is associated with a >1 log lower viral setpoint in C-clade infection 41 
and that this response selects escape mutants within the epitope. We first examined the relationship 42 
of KF11 responses in B-clade infected subjects with HLA-B*57:01 to immune control and observed 43 
that a detectable KF11 response was associated with a >1 log higher viral load (p=0.02). No 44 
evidence of HLA-B*57:01-KF11 associated selection pressure was identified in previous 45 
comprehensive analyses of >1800 B-clade infected subjects infected. We then studied a B-clade 46 
infected cohort in Barbados where HLA-B*57:03 is highly prevalent. In contrast to B-clade 47 
infected subjects expressing HLA-B*57:01, we observed strong selection pressure driven by the 48 
HLA-B*57:03-KF11 response for the escape mutation S173T. This mutation reduces recognition of 49 
virus-infected cells by HLA-B*57:03-KF11 CTL, and is associated with a >1 log increase in viral 50 
load in HLA-B*57:03-positive subjects (p=0.009). We demonstrate functional constraints imposed 51 
by HIV clade relating to the residue at Gag-173 that explain the differential clade-specific escape 52 
patterns in HLA-B*57:03 subjects. Further studies are needed to evaluate the role of the KF11 53 
response in HLA-B*57:01-associated HIV disease protection.  54 
  55 
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IMPORTANCE SECTION 56 
HLA-B*57 is the HLA class I molecule that affords the greatest protection against disease 57 
progression in HIV infection. Understanding the key mechanism(s) underlying immune suppression 58 
of HIV is of importance in guiding therapeutic and vaccine-related approaches to improve the levels 59 
of HIV control occurring in nature. Numerous mechanisms have been proposed to explain the HLA 60 
associations with differential HIV disease outcome but no consensus exists. These studies focus on 61 
two subtypes of HLA-B*57, prevalent in Caucasian and African populations, HLA-B*57:01 and 62 
HLA-B*57:03, respectively. These alleles appear equally protective against HIV disease 63 
progression. The CTL epitopes presented are in many cases identical, and the dominant response in 64 
chronic infection in each case is to the Gag epitope KF11. However, there the similarity ends. This 65 
paper seeks to better understand the reasons for these differences and what this teaches us about 66 
which immune responses are contributing to immune control of HIV infection. 67 
 68 
 69 
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INTRODUCTION 71 
HLA polymorphism has a substantial impact on HIV disease outcome (1-5) and yet the principal 72 
mechanisms underlying these effects remain unresolved (5). The most protective HLA class I 73 
molecule is HLA-B*57. HLA-B*57:01 is the most prevalent subtype in Caucasian populations, 74 
apparently conferring a similar level of protection against HIV disease progression as HLA-75 
B*57:03, the most prevalent subtype in African populations (6). One proposal is that the HLA-76 
B*57-mediated protection is at least in part due to the breadth of the Gag-specific CD8+ T-cell 77 
response, and that HLA-associated immune control of HIV is related to the ability of the CTL 78 
response to drive selection pressure on the virus, such that escape can only be achieved at 79 
significant cost to viral replicative capacity (5, 7-10). However, although HLA-B*57:01 and HLA-80 
B*57:03 appear to present the identical Gag epitopes, previous studies suggest that significant 81 
differences exist in the impact of these responses on immune control.  82 
 83 
The dominant HIV-specific CD8+ T-cell response in each case is directed towards the Gag epitope 84 
KAFSPEVIPMF (‘KF11’, Gag 162-172). Published studies in HLA-B*57:01-positive subjects have 85 
been almost exclusively conducted in B clade infection and these have suggested that a response to 86 
KF11 is not associated with immune control (2, 11) and that the magnitude of HLA-B*57:01-KF11 87 
responses may even be higher in progressors. Evaluation of full-length viral sequences in 1888 B 88 
clade infected subjects failed to identify any sequence polymorphisms within the KF11 epitope or 89 
flanking it that were directly associated with HLA-B*57:01 (12) and that would have suggested 90 
strong selection pressure imposed on the virus by this response. By comparison, 20 HIV amino acid 91 
polymorphisms were identified elsewhere in the HIV proteome that were directly associated with 92 
HLA-B*57:01. In contrast, in studies undertaken in C clade infected African subjects expressing 93 
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HLA-B*57:03, a KF11 response is associated with a >1 log lower viral load (13), and there is 94 
strong evidence of selection pressure within this epitope, with approximately 70% of subjects 95 
carrying mutants at Ala-163 and/or Ser-165, positions 2 and 4 in the epitope (P2 and P4) (9, 10, 14).  96 
 97 
The escape mutants that are selected within KF11 in C clade-infected HLA-B*57:03-positive 98 
subjects are typically A163G and S165N. The A163G mutation is selected first, reducing CTL 99 
recognition, but also significantly lowering viral replicative capacity (14). The S165N mutant is 100 
then selected, substantially restoring viral replicative capacity at the same time as entirely 101 
abrogating recognition: an ideal result for the virus (14) that has been associated with higher viral 102 
loads (15). Thus the impact of the HLA-B*57:03-KF11 response on the virus is consistent with the 103 
mechanism of HLA-mediated immune control described above, with CTL activity forcing the 104 
selection of viral escape mutants that reduce viral replicative capacity, whereas that of the HLA-105 
B*57:01-KF11 response is not consistent with this mechanistic model.  106 
 107 
Initial studies proposed that the HLA-B*57:01-KF11 TCRs are highly conserved, with a dominant 108 
or exclusively expressed V5/V19 TCR in 60-100% of subjects (15, 16). These HLA-B*57:01-109 
KF11 TCRs were more likely than the HLA-B*57:03-KF11 TCRs to recognise epitopes containing 110 
A163G and S165N; hence these mutations would not be selected in individuals expressing HLA-111 
B*57:01 (15, 17). However subsequent studies of HLA-B*57:01-KF11 TCR usage have been 112 
contradictory, with the V5/V19 TCRs identified as the dominant receptor in 0/6 and 2/10 HLA-113 
B*57:01-positive subjects, respectively (11, 18). Thus it appears unlikely that HLA B*57 subtype-114 
specific effects, namely a public TCR clonotype with high functional avidity for HLA-B*57:01-115 
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KF11 (19) fully explain the observed differences in selection of KF11 escape mutants in HLA-116 
B*57:01 and HLA-B*57:03. 117 
 118 
An alternative hypothesis is that escape mutations within KF11 are tolerated in the context of the C-119 
clade, but not in the B-clade Gag sequence, and that this may contribute to the high frequency of 120 
escape mutations within the KF11 epitope in HLA-B*57:03-positive individuals infected with C-121 
clade virus. To address this possibility, we here compared a cohort of B-clade infected subjects in 122 
Barbados, in which the HLA-B*57:03-subtype predominates, with a cohort of C clade infected 123 
subjects in Botswana, where the HLA-B*57:03-subtype also predominates. We identified clade-124 
specific sequence differences that influence the dynamics of viral escape within the HLA-B*57:03-125 
restricted KF11 epitope. These differences were confirmed in a large multi-cohort dataset featuring 126 
3298 subjects (including the Barbados and Botswana cohorts), including 1732 clade C infected 127 
Africans and 1566 clade B infected North Americans. 128 
 129 
  130 
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METHODS 131 
Study cohorts and subjects 132 
HIV-1 B clade infected subjects expressing HLA-B*57:01 were studied from ART-naïve cohorts in 133 
Oxford, UK (the Thames Valley Cohort, as previously described (20) and in Barcelona, Spain (21). 134 
Additional study cohorts for evaluation of HLA-B*57:03 in the context of B clade and C clade 135 
infection in Barbados and Botswana, respectively, were: (i) Bridgetown, Barbados (B-clade, n=246 136 
Median age: 38 years IQR 31-47, female:male ratio 60:40, samples collected between 2008-2010), 137 
where study subjects were attendees at the Ladymeade Reference Clinic; and (ii) Gaborone, 138 
Botswana (C-clade, n=514, Median age; 27 years IQR 23-32, female:male 100:0, samples collected 139 
between 2007-2008), where study subjects were antenatal women from the Mma Bana Study, as 140 
previously described (8, 13, 22, 23).  141 
 142 
Ethics approval was given by the Health Research Development Committee, Botswana Ministry of 143 
Health, by the Barbados Ministry of Health, the Hospital Germans Trias i Pujol' Ethics Committee, 144 
and by the Oxford Research Ethics Committee. Subjects received voluntary testing and counselling 145 
and written informed consent was obtained from all individuals. Viral load in chronic infection was 146 
measured using the Roche Amplicor version 1.5 assay; CD4+ T cell counts were measured by flow 147 
cytometry. Viral load and absolute CD4 count measurements were obtained at study entry 148 
(baseline) for all individuals. All study subjects were ART-naïve. 149 
 150 
Four-digit HLA typing of the Class I locus was performed from genomic DNA as previously 151 
described (24) by sequence-based typing at the ASHI* accredited HLA typing laboratory, 152 
University of Oklahoma Health Sciences Centre, USA. Exons 2 and 3 of HLA Class I were 153 
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amplified by locus-specific PCR and then sequenced. Resolution of ambiguities was undertaken 154 
according to the ASHI committee recommendations. 155 
 156 
Additional viral sequence analyses were performed on two previously described, multi-center 157 
cohorts: (1) the International HIV Adaptation Collaborative (IHAC) consisting of 1443 clade B Gag 158 
sequences (12); and (2) 1470 African clade C Gag sequences from cohorts based in Durban (8), 159 
Bloemfontein (25) and Kimberley (20) South Africa, Zambia and the Thames Valley area of the 160 
United Kingdom (20). Where high-resolution HLA typing was unavailable, we employed a 161 
published machine learning algorithm trained on a dataset of high resolution HLA class I types 162 
from >13,000 individuals with known ethnicity to complete these data to high resolution. (26). 163 
 164 
IFN-γ ELISPOT assays  165 
IFN-γ enzyme-linked immunospot (Elispot) assays were performed as previously described (13, 27), 166 
using optimally defined epitopes and 18mer overlapping peptides (OLP) with input cells/well 167 
ranging from 30,000 to 100,000.  The number of specific spot-forming cells (SFC) was calculated 168 
by subtracting the mean number of spots in the negative control wells from the number of spots 169 
counted in each well. The magnitude of epitope-specific responses was calculated as SFC per 170 
million cells.  171 
 172 
Site-directed mutagenesis of NL43 173 
The mutation S173T (Serine to Threonine at Gag HXB2 position 173) was introduced by site 174 
directed mutagenesis (Quikchange I, Stratagene,UK) into wild-type NL43 plasmid DNA, as well as 175 
NL43 containing the mutations A163G and/or S165N (14). Whole plasmid DNA p83-2 (the 5’-half 176 
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of HIV-1NL43 strain) was PCR-amplified in a mutagenesis reaction with two overlapping primers, 177 
containing the target mutation. Primers used for the mutagenesis reaction were: F 5'-178 
CCCAGAAGTAATACCCATGTTTACGGCATTATCAGAAGGAGC-3' and R 5´-179 
GCTCCTCTGATAATGCCGTAAACATGGGTATTACTTCTGGG-3 (the mutagenesis site is 180 
underlined) .The presence of mutations were verified by DNA Gag sequencing in newly generated 181 
plasmid clones. The DNA fragment ranging from SapI to Apa I restriction sites was then subcloned 182 
into a new p83-2 vector to avoid potential carry over of additional mutations during the 183 
mutagenesis, and the coding region sequence was verified again as previously described (28) 184 
 185 
Virus production and Replication kinetics 186 
Viral stocks were produced by cotransfection of the different site-directed mutant plasmids (5’ half 187 
of HIV-1NL43 strain) with p83-10eGFP (3’ half of HIV-1NL43 strain) into MT4 cells (29). Viral stocks 188 
were harvested and viral RNA extracted (Qiagen, UK). The gag p24/p17 coding region was PCR 189 
amplified and sequenced to confirm the presence of the mutations in the viral RNA and the absence 190 
of any other potential polymorphisms. The 50% tissue culture-infectious dose (TCID50) for each 191 
viral stock was determined in MT4 using the Reed and Muench method (30). For replication 192 
experiments, Jurkat, MT4 and H9 T cells were infected in triplicate with a multiplicity of infection 193 
(MOI) of 0.005 in a total volume of 3ml with wild-type or mutant HIV-1 NL43 virus and incubated 194 
at 37ºC for 2 hours. Pellets were washed twice with PBS and cultured at 37ºC and 5% of CO2. After 195 
infection around 50,000 cells were harvested daily in order to measure infectivity by percentage of 196 
eGFP-positive cells by Fluorescent Activated Cell Sorting (FACS). Replication kinetics were 197 
determined by calculating the mean viral slope using the LOGEST function (Microsoft Excel) and 198 
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converted to natural logs. Variation in replication slopes was assessed using Student’s T test. All 199 
statistical calculations were performed in Prism 5.0 (Graphpad).  200 
 201 
Amplification and sequencing of proviral DNA 202 
Gag p17/p24 sequences (Cohort;Barbados n=125, Botswana n=322) were generated from genomic 203 
DNA extracted from peripheral blood mononuclear cells (PBMC) where available, amplified by 204 
nested PCR using previously published primers to obtain population sequences, as previously 205 
described (31). Sequencing was undertaken using the Big Dye Ready Reaction Terminator Mix 206 
(V3.1) (Applied Biosystems, UK). Sequences were analysed using Sequencher v4.8 (Gene Codes 207 
Corporation) and aligned by SeAl to HXB2 B-clade reference strain. Sequences were submitted to 208 
Genbank and accession numbers are as follows FJ497801-FJ497875, FJ497885-FJ497899, 209 
FJ497901-FJ497905, FJ497907-FJ497916, FJ497918-FJ497950. 210 
 211 
Identification of HLA-associated viral polymorphisms from proviral DNA 212 
HLA-associated viral polymorphisms were identified from proviral DNA using a previously 213 
described method that corrects for phylogeny, HLA linkage disequilibrium and codon-covariation 214 
(8, 32). A q-value statistic, representing the p-value analogue of the false discovery rate (FDR), was 215 
computed for each association. The FDR is the expected proportion of false positives among the 216 
associations identified at a given p-value threshold; for example, among associations q≤0.2, we 217 
expect 20% to be false positives. The phylogenetically corrected methods rely on an inferred 218 
phylogeny. We constructed two phylogenies for this study: (i) a phylogeny consisting of clade B 219 
and C sequences from Barbados and Botswana was constructed using Phyml v2.4.5, under the 220 
general time reversible (GTR) model (33) (ii) a phylogeny consisting of N=3298 p17/p24 221 
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sequences from all cohorts described in this study. This phylogeny was too large for Phyml, so we 222 
employed a 3 stage process to infer the phylogeny. (1) A combined alignment was created, then 223 
sites with >10% missing data were removed, after which sequences with missing data in >10% of 224 
remaining sites were removed (resulting in the above noted N’s); (2) a phylogeny was inferred 225 
separately for clade B and C alignments, using Phyml v2.4.5 under the GTR model); (3) the 226 
resulting phylogenies were joined by adding single common ancestor to the two clade trees, and the 227 
branch lengths were optimized using hyphy, under the GTR model (34).  228 
 229 
PhyloDOR ratio 230 
Identification of HLA-associated polymorphisms and assessment of differential escape between 231 
viral clades and/or closely-related HLA alleles were performed as previously described (12, 32, 35). 232 
Briefly, a maximum –likelihood phylogenetic tree was constructed for each gene, and a model of 233 
conditional adaptation was inferred for each observed amino acid at each codon (32). In this model, 234 
the amino acid is assumed to evolve independently along the phylogeny until it reaches the 235 
observed hosts (tree tips). In each host, the HLA-mediated selection pressure is modeled using a 236 
weighted logistic regression, in which the individual’s HLA repertoire is used as predictors and the 237 
bias is determined by the transmitted sequence (35).  Because the transmitted sequence is not 238 
observed, we average over the possible transmitted sequences, and all possible phylogenetic 239 
histories, as inferred from the phylogeny. Similarly, where high resolution HLA types are not 240 
available, we perform a weighted average over possible completions (12).  241 
 242 
To test for differential escape between HLA-B*57:01 and B*57:03, or to test for clade-specific 243 
effects on selection, interaction variables were added to the phylogenetically-corrected logistic 244 
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regression model and significance was determined via a likelihood ratio test, as previously 245 
described (35). 246 
 247 
Effect of S173T mutation on epitope recognition by KF11-specific CD8+ T cells 248 
CD4+ T cells were enriched from PBMCs from healthy donors expressing HLA-B*57:03 using 249 
negative selection (Dynabeads) and activated for 3-6 days using IL-2 (50U/ml Roche) and PHA 250 
(3ug/ml). KF11-specific CD8+ T cells (<98% specificity) were enriched from PBMCs from HIV-251 
infected donors using tetramers as previously described (36). B*57:03-positive CD4+ T cells were 252 
infected with NL43GFP or NL43GFP containing the S173T mutation as described above. To test for 253 
epitope recognition, epitope-specific CD8+ T cells (<98% specificity) were cocultured with the 254 
HIV-infected CD4+ T cells in the presence of CD107a antibodies (PE-Cy5), 10ug/ml Brefeldin A, 255 
Golgi stop (BD), CD49d and CD28 for 6.5 hours at 37oC in a 5% CO2 incubator. Cells were 256 
stained for surface and intracellular antibodies against CD4 (APC), CD8 (Alexa Fluor 700), MIP1B 257 
(FITC), p24 (PE), IFN-y (PE-Cy7), Live/dead marker (Pacific Blue), and then immediately 258 
acquired by FACS (BD LSRII). 259 
 260 
 261 
  262 
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RESULTS 263 
B clade HLA-B*57:01-KF11 responders have higher viral setpoints than non-responders 264 
Previous studies of B clade infected subjects using peptide-MHC class I tetramers have suggested 265 
that a detectable HLA-B*57:01 response is more frequently observed in progressors (including 266 
those with viral loads of >90,000) than in elite controllers/long-term non-progressors (2, 11). These 267 
studies however were not sufficiently powered to demonstrate a statistically significant result. We 268 
therefore started by comparing responses to KF11 in B clade infected, ART-naïve individuals 269 
expressing HLA-B*57:01 whose viral setpoints ranged from undetectable to 500,000 copies/ml (Fig 270 
1). Here the association between KF11 responders and high viral setpoint reaches statistical 271 
significance (p=0.02, Mann Whitney test). These findings are consistent with the earlier studies 272 
cited of B clade infected subjects expressing HLA-B*57:01, and provide the opposite result to that 273 
obtained in HLA-B*57:03-positive individuals infected with C clade virus (13), using the identical 274 
approach of measuring IFN-g elispot responses to KF11, where a response was associated with a 275 
>10-fold lower viral setpoint. Equivalent studies of KF11 responses in 17 HLA-B*57:03-positive 276 
subjects infected with B clade virus similarly showed substantially lower median viral loads in 277 
KF11 responders compared to non-responders (median viral load 1,629 versus 6,127 c/ml, 278 
respectively), although here this difference did not reach statistical significance (p=0.28, data not 279 
shown). 280 
  281 
Differential escape in the B*57:03-KF11 epitope in B-clade versus C-clade infection  282 
In order to evaluate further the potential differences between HLA-B*57:01 and HLA-B*57:03, we 283 
investigated a B clade infected, ART-naïve study cohort in Barbados where HLA-B*57:03 is highly 284 
prevalent. It has been noted in several other studies that HLA-B*57:03 is associated with immune 285 
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control of HIV in B clade and C clade infection (1-5). Consistent with these studies, HLA-B*57:03-286 
positive subjects in Barbados exhibited significantly lower median viral loads than HLA-B*57:03-287 
negative subjects (median 3,450 versus 13,350, p=0.015, Mann Whitney test) and significantly 288 
higher CD4+ counts (median 565 versus 398, p=0.003 Mann Whitney test) (Fig. 2).  289 
 290 
To determine the nature of any selection pressure imposed in the B clade virus through the HLA-291 
B*57:03 KF11 response, we analysed viral sequences in gag in the Barbados cohort in order to 292 
identify associations between HLA-B*57:03 and viral polymorphisms in the region of the KF11 293 
epitope. This revealed that HLA-B*57:03 expression was associated with the previously described 294 
escape mutations T242N, in the epitope TW10 (TSTLQEQIGW; Gag HXB2 240-249) (7, 39), and 295 
I147X, in the epitope ISW9 (ISPRTLNAW; Gag HXB2 147-155) (Table I) (40, 41). However, the 296 
intra-epitope escape mutations within KF11 (KAFSPEVIPMF; Gag HXB2 162-172), namely 297 
A163G and S165N, selected in approximately 70% of C-clade infected HLA-B*57:03-positive 298 
subjects (3, 14), were not associated with HLA-B*57:03 in this Barbadian study cohort (Table I-II).  299 
 300 
However, in this same Barbados cohort, we identified an HLA-B*57:03-associated viral 301 
polymorphism located at Gag HXB2 position 173, which immediately flanks the C-terminus of the 302 
KF11 epitope. This mutation has not been observed in association with HLA-B*57:03 in studies of 303 
C-clade infected cohorts, which in any case have Threonine as the consensus residue at position 173 304 
(14, 42, 43). The high frequency of selection of S173T by HLA-B*57:03-positive subjects (61% 305 
versus 24% in HLA-B*57:03-positive versus HLA-B*57:03-negative subjects) together with the 306 
lack of any selection of intra-epitope KF11 mutations led to the hypothesis that selection of S173T 307 
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in B-clade virus may mitigate against further selection of KF11 escape mutations A163G and/or 308 
S165N (Table II) (see below).  309 
 310 
We performed a further analysis using a phylogenetically-corrected method (12) to compare the 311 
impact of HLA-B*57:03 on the selection of Gag escape mutants in B-clade versus C-clade HIV, 312 
using data from the study cohorts in Barbados (B-clade) and in Gaborone, Botswana (C-clade). We 313 
found no statistical difference between odds of HLA-B*57:03-mediated escape in the two cohorts 314 
for T242N (p=0.82) or I147L (p=0.29). In contrast, we observed substantial clade differences for all 315 
three KF11 escape mutations: the strength of selection for A163G and S165N was significantly 316 
greater in the C clade cohort (p=0.006 and p=0.08, respectively), whereas 173T was only selected 317 
in the B clade cohort (p=0.0006). In fact, Gag-173T, the consensus in C-clade, arises at 318 
significantly lower frequency in HLA-B*57:03-positive subjects in Botswana (p=0.0062; discussed 319 
further below) (Table III). These data demonstrate clade-specific differences in the impact of HLA-320 
B*57:03 on Gag escape mutant selection, with differential effects at Gag-163, 165 and 173, within 321 
or immediately flanking the dominant KF11 epitope.   322 
 323 
Impact of S173T on recognition of virus-infected target cells and on viral setpoint  324 
The location of the HLA-B*57:03-associated mutation immediately downstream of the KF11 325 
epitope suggests that the S173T mutant reduces processing of the epitope. To test whether the 326 
HLA-B*57:03-associated S173T polymorphism reduces recognition of virus-infected target cells, 327 
CD4+ T cells from HLA-B*57:03+ healthy subjects were infected with NL43 HIV that was either 328 
wildtype, expressing Ser-173, or engineered to express the S173T viral polymorphism. Infected 329 
cells were incubated with HLA-B*57:03-KF11-specific CD8+ T-cells (>98% specific) and the level 330 
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of CD8+ T-cell activation monitored by CD107a and MIP1β expression. We observed that the 331 
S173T mutant indeed significantly reduced recognition by the KF11-specific CD8+ T cells (Fig 3, 332 
p=0.0038, Student’s t test). In the same assay, using CD8+ T-cells specific for the HLA-B*57:03-333 
restricted Pol-specific epitope IATESIVIW (‘IAW9’), no difference were observed in the level of 334 
stimulation by the two viruses on the HLA-B*57:03-restricted IAW9-specific CD8+ T cells (Fig 3). 335 
These data support the hypothesis that S173T specifically reduces presentation of the KF11 epitope 336 
by HLA-B*57:03. Furthermore, mismatched CD4+ T cells induced consistently low levels of 337 
stimulation confirming that activation of the KF11- and IAW9-specific CD8+ T cells was HLA-338 
B*57:03-dependent. 339 
 340 
We next examined the viral setpoints and CD4 counts in HLA-B*57:03-positive subjects with and 341 
without the S173T mutation. Viral loads in HLA-B*57:03-positive subjects with the B-clade 342 
wildtype, Serine at Gag-173, were more than 10-fold lower than in B*57:03-positive subjects with 343 
the S173T polymorphism (median viral load 520 versus 6,905 respectively; p=0.009 Mann Whitney 344 
test). Furthermore, 173S was associated with a substantially higher CD4 count in HLA-B*57:03-345 
positive subjects than 173T (median CD4 count 787 versus 375 respectively; p=0.036 Mann 346 
Whitney test) (Fig. 4). However no differences in median viral load or CD4 counts were observed 347 
in B*57:03-negative subjects with Serine versus Threonine at Gag-173 (median viral load 14,450 348 
versus 10,600 respectively; p=0.949 and median CD4 count 358 versus 374 respectively; p=0.522 349 
Mann Whitney test). These data together support the conclusion that HLA-B*57:03-KF11 350 
responses drive the selection of the S173T mutation in B clade infected individuals expressing 351 
HLA-B*57:03; and that this is an escape mutation in that it reduces recognition of virally infected 352 
targets. These findings are consistent with the hypothesis that this response contributes to HLA-353 
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B*57:03-associated control of HIV, since viral loads are significantly higher in those with the 354 
S173T escape mutation. 355 
 356 
S173T with A163G and S165N significantly reduces viral replicative capacity 357 
The observations above prompt the question: if A163G and S165N are escape mutations frequently 358 
selected in HLA-B*57:03-positive subjects infected with C clade virus, why are they not selected in 359 
HLA-B*57:03-positive subjects with B clade virus infection? To assess the functional significance 360 
of the HLA-B*57:03-associated S173T mutation and the possible impact of this polymorphism on 361 
the selection of A163G and S165N, the viral polymorphisms S173T, A163G, and S165N were 362 
introduced by site-directed mutagenesis into the B-clade backbone of NL43GFP. Infectious viral 363 
stocks were generated by transfecting MT4 T-cells with the relevant DNA constructs. H9, MT4 or 364 
Jurkat T cells were then infected and the rate of viral growth was determined by monitoring the 365 
percentage of GFP-infected cells over 14 days.  366 
 367 
Analysis of the rate of viral growth in MT4, H9 and Jurkat T-cells showed, first, that the S173T 368 
polymorphism had no significant effect on viral fitness in this in vitro system in any of these three 369 
cells lines used (Fig.5 and data not shown). We previously showed that the introduction of A163G 370 
or A163G/S165N into the NL43 backbone significantly reduced viral replicative capacity, with 371 
S165N acting as a partial compensatory mutant for A163G that also completely abrogated 372 
recognition of KF11 (14, 15). Here we observe that the introduction of either A163G or S165N into 373 
the NL43 backbone in combination with S173T also significantly reduces viral spread, but 374 
substantially more so than in the absence of S173T. Furthermore, the combination of S173T and 375 
both of the KF11 mutations, A163G and S165N, dramatically reduced viral spread even further, 376 
 18
indicating a significant cost to viral fitness of this combination of viral mutations in a B clade virus 377 
(Fig. 5). These data together suggest that the KF11 escape mutant S173T is more commonly 378 
selected in B clade infected subjects expressing HLA-B*57:03 because the cost to replicative 379 
capacity is negligible, and less than that resulting from A163G or S165N. Subsequent mutations in 380 
addition to S173T result in such a substantial reduction in replicative capacity, without any apparent 381 
amelioration from S165N to reduce these fitness costs, that these arise very rarely (Table II).  382 
 383 
As mentioned above, Gag-173T, the consensus in C-clade, arises at a significantly lower frequency 384 
in HLA-B*57:03-positive compared to HLA-B*57:03-negative subjects in Botswana (p=0.0062). A 385 
larger analysis of the KF11 epitope region of 1899 C-clade sequences confirmed that the presence 386 
of A163G, S165N or both in combination, was significantly associated with Serine at position 173 387 
and that this was the case both for HLA-B*57:03-positive and HLA-B*57:03-negative individuals 388 
(Fig 6). Thus, although 173T is consensus in C-clade, it appears unfavourable in the context of the 389 
KF11 intra-epitope escape mutations, supporting the findings in B-clade suggesting that this 390 
combination of mutations has a detrimental impact on viral fitness.  391 
 392 
  393 
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DISCUSSION 394 
HLA-B*57:01 and HLA-B*57:03 are the two most protective HLA molecules against HIV disease 395 
progression in both B and C clade infection (5). These molecules differ by only two amino acids 396 
(D114N and S116Y respectively), and the peptide binding motifs are almost indistinguishable (44, 397 
45). In chronic infection, the dominant HIV-specific CD8+ T cell response in subjects expressing 398 
HLA-B*57:01 or HLA-B*57:03 is to the Gag epitope KAFSPEVIPMF (‘KF11’, Gag HXB2 162-399 
172) (2, 10, 13). Studies of HLA-B*57:03-positive subjects infected with C clade virus indicate that 400 
this KF11 response makes an important contribution to immune control (3, 15), and contributes to 401 
the superiority of HLA-B*57:03 as a protective HLA class I molecule over the closely-related 402 
HLA-B*57:02 and HLA-B*58:01. (10). 403 
 404 
This study sets out to investigate the observations, first, that whilst the HLA-B*57:03-KF11 405 
response is associated with significantly lower viral setpoints in C clade infection (13), studies of 406 
HLA-B*57:01-KF11 responses had suggested the opposite in B clade infected indiviuduals (2, 11); 407 
and, second, whereas the HLA-B*57:03-KF11 response frequently drives escape mutations within 408 
KF11 in C clade infection (A163G and S165N) (8), these are not selected in response to HLA-409 
B*57:01 responses in B clade infection (12).  410 
 411 
We first confirmed a statistically significant association between response to the KF11 epitope in B 412 
clade infected subjects expressing HLA-B*57:01 and a >1 log higher viral load. This result arose 413 
from the identical assays that were used in the studies that showed a KF11 response was a 414 
associated with a >1 log lower viral load in C clade infected subjects expressing HLA-B*57:03 415 
(13). We next showed that HLA-B*57:03 has a similar impact in B and C clade infection in terms 416 
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of the escape mutations selected in the Gag epitopes ISW9 and TW10, but a differential impact in 417 
the KF11 epitope. The S173T mutation selected in B clade infection reduces recognition of virus-418 
infected targets and is associated with a >1 log increase in viral setpoint. This is consistent with 419 
studies in C clade infection (15) suggesting that this HLA-B*57:03 KF11 response contributes to 420 
HLA-B*57:03-associated immune control of HIV infection. The clade specific differences in the 421 
selection of KF11-driven escape mutants observed in Barbados (B clade infected cohort) and 422 
Botswana (C clade infected cohort) were corroborated in analyses of larger datasets. 423 
 424 
The position of S173T one residue downstream (P1’) of the KF11 epitope suggests that it may be a 425 
processing mutation since this residue would be involved in the cleavage site of the proteasome 426 
(46). Previous studies of peptide cleavage motifs have suggested that the constitutive- and immuno-427 
proteasome have a strong preference for Alanine at P1’ but prefer Serine over Threonine; thus the 428 
mutation S173T could affect efficient cleavage of the C-terminal end of the KF11 epitope by the 429 
proteasome (46).  430 
 431 
We show that the HLA-B*57:03-associated S173T mutation effectively precludes further selection 432 
of the KF11 intra-epitope viral mutations, A163G and S165N, since the combination of these three 433 
mutations in a clade B backbone results in a virus with severely reduced replicative capacity. 434 
Indeed, the close proximity of the amino acid positions 173, 163 and 165 between helix 1 and helix 435 
2 of the Gag p24 structure, suggests that structural constraints prevent selection of A163G and 436 
S165N if S173T has already been selected. Previous work has shown that, using a B-clade 437 
backbone, and in the presence of S173, the mutation A163G reduces replicative capacity, but that 438 
the further addition of S165N, as observed in vivo, partially restores replicative capacity (14, 47). 439 
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This fits with the order of selection of A163G and S165N, with S165N apparently always arising 440 
subsequent to A163G (14). However in B clade infection it appears that the selection of S173T 441 
prevents the selection of further mutants within the epitope because the fitness cost is too high. 442 
S173T appears to be the preferred choice of viral escape from the KF11-specific response since it 443 
has minimal effect on viral fitness.  444 
Our inference from the data described above and from previous studies (23) indicating that the 445 
HLA-B*57:03-KF11 response contributes to immune control of B and C clade HIV infection. The 446 
reduced recognition of S173T-virus-infected cells by KF11-specific CTL together with the lack of 447 
cost to viral replicative capacity resulting from S173T is consistent with the observation that viral 448 
loads are higher and CD4 counts lower in B clade infected subjects expressing HLA-B*57:03. 449 
 450 
In view of the substantial reduction in viral replicative capacity resulting from the 451 
A163G/S165N/S173T combination in B clade infection, it is perhaps surprising to observe the 452 
selection of A163G/S165N at high frequency in HLA-B*57:03-positive subjects infected with C 453 
clade virus in which the vast majority of sequences carry Thr at Gag-173. It may be inferred from 454 
this that the presence of consensus 173-Thr in the context of C clade Gag does not have the same 455 
prohibitive effect on viral fitness, as it does not prevent the selection of A163G and S165N. 456 
Nevertheless, in C clade infection, both in HLA-B*57:03-positive and HLA-B*57:03-negative 457 
individuals, A163G/S165N are significantly associated with Ser at Gag-173 (Fig. 6), as opposed to 458 
the consensus Thr at this position, suggesting that the combination of A163G/S165N/S173T is not 459 
favoured in either B or C clade infection.  460 
 461 
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Gag-173 has been well-studied in relation to HLA-B*27, another protective HLA molecule, 462 
because of the S173A mutation that accompanies the R264K escape variant within the dominant 463 
HLA-B*27-restricted epitope KRWIILGLNK (KK10) (48-50). It is noteworthy that in C clade 464 
infection, R264K escape in HLA-B*27-positive subjects is typically accompanied by compensatory 465 
mutations not at Gag-173, but at S165N (Brener et al, in preparation). These data underline the tight 466 
constraints on amino acid substitutions in the capsid protein, the interdependence of residues at 467 
certain key positions in the structure, including Gag-163, Gag-165, and Gag-173, and therefore the 468 
impact that clade can have on the escape options for the virus. 469 
 470 
These data help to explain why HLA-B*57:03 is not associated with the ‘usual’ KF11 intra-epitope 471 
mutations A163G/S165N in clade B, but they do not explain why HLA-B*57:01 is not associated 472 
with either the S173T flanking mutation, nor with any KF11 intra-epitope mutations. Previous 473 
studies have suggested that TCR usage for the HLA-B*57:01-KF11 response allows recognition of 474 
the KF11 variants (15), but these initial TCR studies indicating conservation of a ‘public’ HLA-475 
B*57:01-KF11 TCR have not been borne out by subsequent studies (11, 18). One possible 476 
explanation is that the potency of the HLA-B*57:01-KF11 response is so great that a moderate 477 
reduction in processed epitope would not affect killing sufficiently to be selected, however 478 
preliminary data suggests that HLA-B*57:03 response is, if anything, the more potent. Further 479 
studies with a large number of KF11-specific clones would be needed to establish whether clear-cut 480 
differences between the responses restricted by HLA-B*57:03 and HLA-B*57:01 exist in terms of 481 
potency, and the relevance of this to viral escape patterns.  A recent study comparing the impact of 482 
individual HLA class I molecules on immune control (viral load <2000 copies/ml) versus non-483 
control (VL>10,000 copies/ml) of B clade infection showed the identical odds ratio for protection 484 
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via HLA-B*57:01 in a European American cohort as via HLA-B*57:03 in an African American 485 
cohort (6). 486 
 487 
These studies therefore provide an explanation for the distinct clade-specific selection of escape 488 
mutants by the HLA-B*57:03-KF11 response but do not resolve the question of why the HLA-489 
B*57:01-KF11 response does not select escape mutants. Insufficient studies have been undertaken 490 
in C clade infected subjects who express HLA-B*57:01 to be certain of whether this response 491 
selects no escape mutants in C clade as well as in B clade infection. The absence of the KF11 492 
response in elite controllers with HLA-B*57:01 does not necessarily mean that these responses 493 
have not contributed to immune control in these subjects, since it is possible that the period of 494 
detectability may be transient. It is clear that many responses that are undetectable in elite 495 
controllers can become detectable after peptide stimulation (51). However, if the KF11-specific 496 
CTL response contributes to immune control of HIV in HLA-B*57:01-positive subjects in B clade 497 
infection, it would be unique in failing to select escape mutants in the process and the mechanism 498 
would be invaluable for directing successful vaccine targets. 499 
 500 
Funding acknowledgements  501 
PJRG is supported by the Wellcome Trust and the NIH (RO1 AI046995). ZLB is the recipient of a 502 
New Investigator Award from the Canadian Institutes of Health Research and a Scholar Award 503 
from the Michael Smith Foundation for Health Research.   504 
 505 
 506 
 507 
 24
 508 
 509 
 510 
 511 
 512 
 513 
514 
 25
REFERENCES 515 
1. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler 516 
C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL. 1996. 517 
Influence of combinations of human major histocompatibility complex genes on the course 518 
of HIV-1 infection. Nature medicine 2:405-411. 519 
2. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, 520 
Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. 2000. HLA B*5701 is 521 
highly associated with restriction of virus replication in a subgroup of HIV-infected long 522 
term nonprogressors. Proceedings of the National Academy of Sciences of the United States 523 
of America 97:2709-2714. 524 
3. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu 525 
P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo 526 
MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman 527 
P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ. 2004. Dominant 528 
influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 529 
432:769-775. 530 
4. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme 531 
CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, 532 
Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, 533 
Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, 534 
Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss 535 
KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, 536 
Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, 537 
Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, 538 
Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, 539 
Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, 540 
Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie 541 
W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, 542 
Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, 543 
Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush 544 
LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, 545 
Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, 546 
Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, 547 
Jr., Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, 548 
Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, 549 
Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs 550 
JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, 551 
Jr., Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston 552 
C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins 553 
TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, 554 
Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson 555 
JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou 556 
H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, 557 
Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman 558 
MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, 559 
 26
Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour 560 
MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Jr., Mayer KH, 561 
McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, McLeod GX, 562 
Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, 563 
Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, 564 
O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, 3rd, Olender SA, 565 
Ostrowski M, Owen WF, Jr., Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce 566 
MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, 567 
Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, 568 
Rodriguez M, Rose RC, 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, 569 
Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt 570 
W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore 571 
JM, Jr., Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett 572 
S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, 573 
Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, 574 
Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, 575 
Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber 576 
RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, 577 
van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, 578 
Zeeman B, Zhao M. 2010. The major genetic determinants of HIV-1 control affect HLA 579 
class I peptide presentation. Science (New York, N.Y 330:1551-1557. 580 
5. Goulder PJ, Walker BD. 2012. HIV and HLA class I: an evolving relationship. Immunity 581 
37:426-440. 582 
6. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, 583 
Goulder P, Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, 584 
Heckerman D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, 585 
Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks 586 
SG, Pereyra F, Walker B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington 587 
M. 2013. Influence of HLA-C expression level on HIV control. Science (New York, N.Y 588 
340:87-91. 589 
7. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes 590 
EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas 591 
SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-592 
Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ. 2004. 593 
HIV evolution: CTL escape mutation and reversion after transmission. Nature medicine 594 
10:282-289. 595 
8. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, Rolland 596 
M, Honeyborne I, Carlson J, Kadie C, Brander C, Bishop K, Mlotshwa N, Mullins JI, 597 
Coovadia H, Ndung'u T, Walker BD, Heckerman D, Goulder PJ. 2008. Central role of 598 
reverting mutations in HLA associations with human immunodeficiency virus set point. 599 
Journal of virology 82:8548-8559. 600 
9. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, Tang J, Farmer P, 601 
Ndung'u T, Lakhi S, Gilmour J, Goepfert P, Walker BD, Kaslow R, Mulenga J, Allen 602 
S, Goulder PJ, Hunter E. 2009. Evolution of HLA-B*5703 HIV-1 escape mutations in 603 
HLA-B*5703-positive individuals and their transmission recipients. The Journal of 604 
experimental medicine 206:909-921. 605 
 27
10. Kloverpris HN, Stryhn A, Harndahl M, van der Stok M, Payne RP, Matthews PC, 606 
Chen F, Riddell L, Walker BD, Ndung'u T, Buus S, Goulder P. 2012. HLA-B*57 607 
Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection 608 
pressure, and HIV immune control. Journal of virology 86:919-929. 609 
11. Mendoza D, Royce C, Ruff LE, Ambrozak DR, Quigley MF, Dang T, Venturi V, Price 610 
DA, Douek DC, Migueles SA, Connors M. 2012. HLA B*5701-positive long-term 611 
nonprogressors/elite controllers are not distinguished from progressors by the clonal 612 
composition of HIV-specific CD8+ T cells. Journal of virology 86:4014-4018. 613 
12. Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK, 614 
Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, 615 
Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL. 616 
2012. Correlates of protective cellular immunity revealed by analysis of population-level 617 
immune escape pathways in HIV-1. Journal of virology 86:13202-13216. 618 
13. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, 619 
Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, 620 
Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy 621 
N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman 622 
D, Walker BD, Goulder P. 2007. CD8+ T-cell responses to different HIV proteins have 623 
discordant associations with viral load. Nature medicine 13:46-53. 624 
14. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, van der Stok M, 625 
Mncube Z, Brander C, Rousseau C, Mullins JI, Kaslow R, Goepfert P, Allen S, Hunter 626 
E, Mulenga J, Kiepiela P, Walker BD, Goulder PJ. 2007. Compensatory mutation 627 
partially restores fitness and delays reversion of escape mutation within the 628 
immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency 629 
virus type 1 infection. Journal of virology 81:8346-8351. 630 
15. Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, Frahm N, Feeney 631 
ME, Tang Y, Pereyra F, Labute MX, Pfafferott K, Leslie A, Crawford H, Allgaier R, 632 
Hildebrand W, Kaslow R, Brander C, Allen TM, Rosenberg ES, Kiepiela P, Vajpayee 633 
M, Goepfert PA, Altfeld M, Goulder PJ, Walker BD. 2007. Mutually exclusive T-cell 634 
receptor induction and differential susceptibility to human immunodeficiency virus type 1 635 
mutational escape associated with a two-amino-acid difference between HLA class I 636 
subtypes. Journal of virology 81:1619-1631. 637 
16. Gillespie GM, Stewart-Jones G, Rengasamy J, Beattie T, Bwayo JJ, Plummer FA, 638 
Kaul R, McMichael AJ, Easterbrook P, Dong T, Jones EY, Rowland-Jones SL. 2006. 639 
Strong TCR conservation and altered T cell cross-reactivity characterize a B*57-restricted 640 
immune response in HIV-1 infection. J Immunol 177:3893-3902. 641 
17. Stewart-Jones GB, Simpson P, van der Merwe PA, Easterbrook P, McMichael AJ, 642 
Rowland-Jones SL, Jones EY, Gillespie GM. 2012. Structural features underlying T-cell 643 
receptor sensitivity to concealed MHC class I micropolymorphisms. Proceedings of the 644 
National Academy of Sciences of the United States of America 109:E3483-3492. 645 
18. Simons BC, Vancompernolle SE, Smith RM, Wei J, Barnett L, Lorey SL, Meyer-Olson 646 
D, Kalams SA. 2008. Despite biased TRBV gene usage against a dominant HLA B57-647 
restricted epitope, TCR diversity can provide recognition of circulating epitope variants. J 648 
Immunol 181:5137-5146. 649 
19. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, Hartman KL, Henry 650 
LM, Brenchley JM, Ruff LE, Venturi V, Pereyra F, Sidney J, Sette A, Douek DC, 651 
 28
Walker BD, Kaufmann DE, Brander C. 2011. High-functional-avidity cytotoxic T 652 
lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative 653 
HIV control. Journal of virology 85:9334-9345. 654 
20. Matthews PC, Adland E, Listgarten J, Leslie A, Mkhwanazi N, Carlson JM, Harndahl 655 
M, Stryhn A, Payne RP, Ogwu A, Huang KH, Frater J, Paioni P, Kloverpris H, Jooste 656 
P, Goedhals D, van Vuuren C, Steyn D, Riddell L, Chen F, Luzzi G, Balachandran T, 657 
Ndung'u T, Buus S, Carrington M, Shapiro R, Heckerman D, Goulder PJ. 2011. HLA-658 
A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with 659 
HLA-B*5703. J Immunol 186:5675-5686. 660 
21. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, Ruiz-Riol M, 661 
Berger CT, Herrero MJ, Palou E, Plana M, Rolland M, Khatri A, Heckerman D, 662 
Pereyra F, Walker BD, Weiner D, Paredes R, Clotet B, Felber BK, Pavlakis GN, 663 
Mullins JI, Brander C. 2012. CTL responses of high functional avidity and broad variant 664 
cross-reactivity are associated with HIV control. PloS one 7:e29717. 665 
22. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo 666 
S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare 667 
E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, 668 
Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, 669 
Mazhani L, Essex M. 2010. Antiretroviral regimens in pregnancy and breast-feeding in 670 
Botswana. The New England journal of medicine 362:2282-2294. 671 
23. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, Wang 672 
B, Losina E, Miura T, Chonco F, van der Stok M, Mncube Z, Bishop K, Goulder PJ, 673 
Walker BD, Brockman MA, Ndung'u T. 2010. Gag-protease-mediated replication 674 
capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical 675 
parameters. Journal of virology 84:10820-10831. 676 
24. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, Welsh KI. 677 
1995. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, 678 
DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-679 
SSP). Tissue antigens 46:355-367. 680 
25. Huang KH, Goedhals D, Fryer H, van Vuuren C, Katzourakis A, De Oliveira T, 681 
Brown H, Cassol S, Seebregts C, McLean A, Klenerman P, Phillips R, Frater J. 2009. 682 
Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free 683 
State, South Africa. Antiviral therapy 14:975-984. 684 
26. Listgarten J, Brumme Z, Kadie C, Xiaojiang G, Walker B, Carrington M, Goulder P, 685 
Heckerman D. 2008. Statistical resolution of ambiguous HLA typing data. PLoS 686 
computational biology 4:e1000016. 687 
27. Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly 688 
RP, Kalams SA, Burchett SA, McIntosh K, Walker BD, Goulder PJ. 2000. 689 
Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-690 
lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked 691 
immunospot assay. Journal of virology 74:8541-8549. 692 
28. Prado JG, Honeyborne I, Brierley I, Puertas MC, Martinez-Picado J, Goulder PJ. 693 
2009. Functional consequences of human immunodeficiency virus escape from an HLA-694 
B*13-restricted CD8+ T-cell epitope in p1 Gag protein. Journal of virology 83:1018-1025. 695 
29. Weber J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, Kazanjian P, 696 
Quinones-Mateu ME. 2006. Use of a novel assay based on intact recombinant viruses 697 
 29
expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution 698 
of pol and env genes to overall HIV-1 replicative fitness. Journal of virological methods 699 
136:102-117. 700 
30. Muench L.J. aHR. 1938. A simple method of estimating fifty percent endpoints. Am. J. 701 
Hyg.:493-497. 702 
31. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L, 703 
Thobakgale C, Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, 704 
Sewell AK, Moore S, Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, 705 
Klenerman P, Korber B, Kiepiela P, Walker B, Goulder P. 2005. Transmission and 706 
accumulation of CTL escape variants drive negative associations between HIV 707 
polymorphisms and HLA. The Journal of experimental medicine 201:891-902. 708 
32. Carlson JM, Brumme ZL, Rousseau CM, Brumme CJ, Matthews P, Kadie C, Mullins 709 
JI, Walker BD, Harrigan PR, Goulder PJ, Heckerman D. 2008. Phylogenetic 710 
dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 711 
Gag. PLoS computational biology 4:e1000225. 712 
33. Guindon S, Gascuel O. 2003. A simple, fast, and accurate algorithm to estimate large 713 
phylogenies by maximum likelihood. Systematic biology 52:696-704. 714 
34. Pond SL, Frost SD, Muse SV. 2005. HyPhy: hypothesis testing using phylogenies. 715 
Bioinformatics 21:676-679. 716 
35. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD, Ndung'u T, Shapiro 717 
R, Frater J, Brumme ZL, Goulder PJ, Heckerman D. 2012. Widespread impact of HLA 718 
restriction on immune control and escape pathways of HIV-1. Journal of virology 86:5230-719 
5243. 720 
36. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling 721 
S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ. 722 
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted 723 
CD8+ T cells. Journal of virology 84:10543-10557. 724 
37. Sacha JB, Chung C, Reed J, Jonas AK, Bean AT, Spencer SP, Lee W, Vojnov L, 725 
Rudersdorf R, Friedrich TC, Wilson NA, Lifson JD, Watkins DI. 2007. Pol-specific 726 
CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated 727 
major histocompatibility complex class I downregulation. Journal of virology 81:11703-728 
11712. 729 
38. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling 730 
S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ. 2010. 731 
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted 732 
CD8+ T cells. Journal of virology 84:10543-10557. 733 
39. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, Walker BD, 734 
Goulder PJ. 2004. Immune escape precedes breakthrough human immunodeficiency virus 735 
type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-736 
positive long-term-nonprogressing child. Journal of virology 78:8927-8930. 737 
40. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C, Holmes EC, 738 
Chang SC, Feeney ME, Addo MM, Ruiz L, Ramduth D, Jeena P, Altfeld M, Thomas S, 739 
Tang Y, Verrill CL, Dixon C, Prado JG, Kiepiela P, Martinez-Picado J, Walker BD, 740 
Goulder PJ. 2004. Immune selection for altered antigen processing leads to cytotoxic T 741 
lymphocyte escape in chronic HIV-1 infection. The Journal of experimental medicine 742 
199:905-915. 743 
 30
41. Boutwell CL, Rowley CF, Essex M. 2009. Reduced viral replication capacity of human 744 
immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape 745 
mutations in HLA-B57 epitopes of capsid protein. Journal of virology 83:2460-2468. 746 
42. Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, Seoighe C, 747 
Treurnicht F, de Rosa DA, Hide W, Karim SA, Gray CM, Williamson C. 2008. 748 
Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a 749 
survival advantage. PLoS pathogens 4:e1000033. 750 
43. Huang KH, Goedhals D, Carlson JM, Brockman MA, Mishra S, Brumme ZL, Hickling 751 
S, Tang CS, Miura T, Seebregts C, Heckerman D, Ndung'u T, Walker B, Klenerman 752 
P, Steyn D, Goulder P, Phillips R, van Vuuren C, Frater J. 2011. Progression to AIDS in 753 
South Africa Is Associated with both Reverting and Compensatory Viral Mutations. PloS 754 
one 6:e19018. 755 
44. Barber LD, Percival L, Arnett KL, Gumperz JE, Chen L, Parham P. 1997. 756 
Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding 757 
influence on peptide-binding specificity. J Immunol 158:1660-1669. 758 
45. Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, Oseroff C, 759 
Lu S, Jakoncic J, de Oliveira CA, Yang L, Mei H, Shi L, Shabanowitz J, English AM, 760 
Wriston A, Lucas A, Phillips E, Mallal S, Grey HM, Sette A, Hunt DF, Buus S, Peters 761 
B. 2012. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide 762 
repertoire. Proceedings of the National Academy of Sciences of the United States of 763 
America 109:9959-9964. 764 
46. Toes RE, Nussbaum AK, Degermann S, Schirle M, Emmerich NP, Kraft M, Laplace 765 
C, Zwinderman A, Dick TP, Muller J, Schonfisch B, Schmid C, Fehling HJ, Stevanovic 766 
S, Rammensee HG, Schild H. 2001. Discrete cleavage motifs of constitutive and 767 
immunoproteasomes revealed by quantitative analysis of cleavage products. The Journal of 768 
experimental medicine 194:1-12. 769 
47. Boutwell CL, Carlson JM, Lin TH, Seese A, Power KA, Peng J, Tang Y, Brumme ZL, 770 
Heckerman D, Schneidewind A, Allen TM. 2013. Frequent and variable cytotoxic-T-771 
lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 772 
subtype B Gag proteins. Journal of virology 87:3952-3965. 773 
48. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, Workman C, 774 
Shaunak S, Olson K, Goulder P, Brander C, Ogg G, Sullivan JS, Dyer W, Jones I, 775 
McMichael AJ, Rowland-Jones S, Phillips RE. 2001. Clustered mutations in HIV-1 gag 776 
are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte 777 
responses. The Journal of experimental medicine 193:375-386. 778 
49. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, 779 
Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, 780 
Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM. 781 
2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in 782 
Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 783 
replication. Journal of virology 81:12382-12393. 784 
50. Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, Suscovich TJ, Li B, 785 
Adam RI, Allgaier RL, Mothe BR, Kuntzen T, Oniangue-Ndza C, Trocha A, Yu XG, 786 
Brander C, Sette A, Walker BD, Allen TM. 2008. Structural and functional constraints 787 
limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-788 
 31
restricted epitope in human immunodeficiency virus type 1 capsid. Journal of virology 789 
82:5594-5605. 790 
51. Ndhlovu ZM, Proudfoot J, Cesa K, Alvino DM, McMullen A, Vine S, Stampouloglou 791 
E, Piechocka-Trocha A, Walker BD, Pereyra F. 2012. Elite controllers with low to absent 792 
effector CD8+ T cell responses maintain highly functional, broadly directed central memory 793 
responses. Journal of virology 86:6959-6969. 794 
 795 
 796 
797 
 32
FIGURE LEGENDS 798 
Figure 1. Median Viral of KF11 responders versus nonresponders in B clade-infected 799 
individuals expressing HLA-B*57:01 800 
PBMCs from B clade-infected, ART-naïve individuals expressing HLA-B*57:01 were analysed by 801 
IFN-γ ELISPOT assay for responses to the KF11 epitope. Viral loads of responders and 802 
nonresponders were compared. Mann-Whitney U tests were performed. 803 
 804 
Figure 2. Median Viral Load and CD4 count of B*57:03-positive versus B*57:03-negative 805 
subjects in Barbados cohort (B-clade). 806 
B*57:03-positive subjects were compared to B*57:03-negative subjects for (A) Viral Load and (B) 807 
CD4 count. Median and 5-95 percentiles are shown. Mann-Whitney U tests were performed. 808 
 809 
Figure 3.Effect of viral mutation S173T on epitope recognition of HIV-infected cells by KF11-810 
specific CD8+ T-cells 811 
Ex vivo CD4+ T-cells from B*57:03+ and B*57:03- donors were infected with wildtype NL43 virus 812 
or NL43 virus harbouring the S173T viral mutation. Infected CD4+ T-cells were then cultured with 813 
KF11-specific CD8+ T-cells (A) or IAW9-specific CD8+ T-cells (B) and the level of CD8+ T-cell 814 
activation monitored by expression of CD107 and Mip1β. Data from both experiments were 815 
standardized relative to % recognition by wildtype virus (C). Experiments were performed in 816 
triplicate, mean and SD are shown. Student’s t test were performed. p value summary is as follows; 817 
p<0.01 *, p<0.001 **, p<0.0001 ***.  818 
 819 
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Figure 4. Median Viral Load and CD4 count of B*57:03-positive HIV-infected subjects with 820 
viral polymorphisms S173 and T173. 821 
Proviral DNA sequences from B*57:03-positive subjects from the Barbados cohort (B-clade) were 822 
analysed for the presence of the viral polymorphisms S173 and T173. Viral Loads (A) and CD4 823 
counts (B) were compared. Median and 5-95 percentiles are shown. Mann-Whitney t tests were 824 
performed. 825 
 826 
Figure 5. Viral replication capacity of NL43GFP virus with multiple B*57:03-associated viral 827 
mutations 828 
NL43 GFP virus was engineered to contain combinations of the viral mutations 173T, 163G and 829 
165N. MT4 cells were infected and monitored for GFP-positive cells over 14 days (A). The slope of 830 
the curve was calculated from the exponential growth phase using the LOGEST function and 831 
converted to natural logs (B). Experiments were performed in triplicate and mean and SD are 832 
shown. Dunnett’s multiple comparison tests were performed. p value summary is as follows; 833 
p<0.01 *, p<0.001 **, p<0.0001 ***. 834 
 835 
Figure 6. Frequency of KF11 mutations (A163G and S165N) and S173T in C-clade gag 836 
sequences (n=1899) 837 
HIV-1 p24 gag sequences (n=1899) were analysed for the presence of the KF11 mutations, A163G 838 
and S165N, in the presence of 173T and 173S. B*57:03-positive subjects (A) and B*57-negative 839 
subjects (B) were analysed. Fisher’s exact tests were performed. 840 
 841 
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 843 
 844 
Table I. Summary of HLA-B*57:03-associated viral mutations in Barbados cohort (n=125). 845 
A phylogenetically-corrected method was used to determine the location of HLA-B*57:03-846 
associated viral mutations in proviral gag p17 and p24. Polymorphism location and HXB2 number 847 
are shown. A q value cut-off of q<0.2 was used. 848 
 849 
Table II. Summary of amino acid polymorphisms in the KF11 epitope region (HXB2 162-173) 850 
in Barbados cohort (n=125). 851 
Proviral sequences were grouped into those from HLA-B*57:03-positive and B*57:03-negative 852 
donors. A summary of all HIV-1 polymorphisms is shown for HXB2 region 162-173. 853 
 854 
Table III Summary of PhyloDOR of B*57:03-associated mutations located in HIV-1 p24 gag 855 
between Barbados [BB] and Botswana [BW] cohorts. 856 
Proviral sequences from Barbados (n=125) and Botswana (n=322) were analysed from HLA-857 
B*57:03-positive and -B*57:03-negative individuals for the presence of B*57:03-associated viral 858 
mutations located in known viral epitopes in p24 gag. HXB2 position of mutations is shown. p 859 
values were calculated from phylogenetically-corrected Odds ratios (PhyloDOR) using an online 860 
tool (35). 861 
 862 
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